Navigation Links
Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Date:2/12/2009

RICHMOND, Va., Feb. 12 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals focused on niche markets with unmet medical needs, announced today that it has entered into a definitive agreement with Merck & Co., Inc. whereby Merck, through an affiliate, will purchase all assets related to Insmed's follow-on biologics platform. Under the terms of the agreement, Insmed will receive a total of $130 million for the assets. After fees, taxes and other costs related to the transaction, Insmed expects net proceeds of approximately $123 million as a result of this agreement.

As part of this transaction, Insmed will receive initial payments of up to $10 million for Insmed's lead follow-on-biologic candidates and the remaining balance upon closing of the transaction, which is targeted for March 31, 2009. These initial payments will allow the Company to maintain its normal business operations throughout the closing period without the need for dilutive financing.

Insmed's follow-on biologics assets include INS-19 and INS-20, whose development and commercial rights will now belong to Merck, as well as the Boulder, Colorado-based manufacturing facility. Merck intends to assume the facility's lease and ownership of all the equipment in the building. In addition, upon closing of the transaction, Merck intends to offer positions to employees of the Boulder facility. Insmed will retain its Richmond, VA corporate office, which houses its Clinical, Regulatory, Finance, and Administrative functions, in support of the continuing IPLEX(TM) program.

"We have long maintained that our follow-on biologics assets hold substantial value, and this agreement with Merck, one of the largest pharmaceutical companies in the world, is a testament to that value," said Dr
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
2. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
3. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
4. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
5. Insmed to Seek Shareholder Approval for Reverse Split
6. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
7. Insmed to Present at Biosimilars 2008 Conference
8. Insmed to Present at BioPharm Asia 2008 Conference
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. Insmed CEO to Present at Drug Discovery & Development Conference
11. Insmed to Host Second Quarter 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... 2013 Rust removal is one of home ... items could be damaged. To help rust contractors make it ... no-scrubbing rust remover it called Rusterizer. It announced ... 10% discount. , My Cleaning Products explained that rust could ... by staining them. The first one, it said, happens ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 Oven Industries, ... temperature controllers and temperature sensors since 1964. ... used in industrial control system applications. As ... device includes a generic, control loop feedback system, which ... expertly used to adjust a systematic process, using a ...
(Date:5/16/2013)... May 16, 2013  HealthSparq, a trusted provider ... nation,s largest regional health plans, will debut a ... Plans (AHIP) Institute 2013 conference on June 13. ... showing how health insurance companies across the country ... and marketplace demands for increased healthcare transparency. ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2New PID Temperature Controllers Announced by Oven Industries Inc. 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... 20 On Wednesday, April 29, 2009, Wyeth (NYSE: ... first quarter. The Company will hold a forty-five minute conference ... April 29, 2009. Interested investors and others may listen ... our Internet webcast, which may be accessed by visiting our ...
... biofuels, biochemicals and textile processingPALO ALTO, Calif., March ... Yesterday, Genencor, a division of Danisco A/S, hosted ... and Development headquarters to a group of industry ... announced collaborations for developing sustainable fuels, chemicals, and ...
... CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... announced updated clinical results from its U.K. combination ... advanced cancers. The principal investigator for the trial ... County Hospital, U.K. The results were presented at ...
Cached Biology Technology:Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings 2Genencor Shows How Industrial Biotech Breakthroughs Contribute to the New Green Economy 2Genencor Shows How Industrial Biotech Breakthroughs Contribute to the New Green Economy 3Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 2Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 3
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
(Date:5/17/2013)... of a group of proteins in the brain responsible ... new target that could increase cell survival. , The ... Biochemistry and published in the EMBO journal ... to new therapies for stroke and other brain diseases. ... team which identified a protein, known as SUMO, responsible ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
... of Texas Medical School at Houston have discovered an ... The decade-long study looked at more than 1,500 DNA ... defect. UT Medical School researchers tested variants in ... to look for a link between genetic variation in ...
... The Argentine ant, Linepithema humile, is one of the most ... five continents in addition to its native range in South ... its success. The findings, from researchers at the University ... appear this week in the Proceedings of the National Academy ...
... structures with pores at both the nanometer and micron ... next generation of detonators used to improve the reliability, ... military munitions. Developed by a team ... and the Indian Head Division of the Naval Surface ...
Cached Biology News:UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2Ant invaders eat the natives, then move down the food chain 2Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
... for all tested applications). ... from within residues 500 to the C-terminus of ... is proprietary) (Peptide available as ... ID: 51043 Swiss Protein ...
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
...
Biology Products: